Families impacted by rare kidney diseases live in uncertainty and fear. These diseases are largely “invisible,” meaning patients suffer in isolation and face criticism from others who minimize their illness with comments like, “Can’t you just get a transplant?” or “You don’t look sick.” On top of being rare, many of these kidney diseases are chronic, complex conditions plagued by rollercoaster cycles of remission and relapse.
Make a difference
in the lives of
rare kidney patients.
Rare kidney disease patients
and their families
Fortunately, recent government action and a novel clinical trial endpoint have encouraged more innovation in the space. We just need to make sure that our systems are ready to take advantage of these innovations.
That’s why we convened patients, healthcare providers, diversity health organizations, diagnostic companies, biotechnology manufacturers, payers, and rare disease organizations to develop high-level policy recommendations to usher in a new era of rare kidney disease care.
Powered by:
Until very recently, clinical trials in kidney disease were virtually nonexistent. While other chronic and acute diseases saw significant leaps in innovation, kidney disease treatment innovation was stagnant.
Get Involved: Which of these recommendations tops your/your organization’s priorities list?
deserve better.
Privacy Policy
RareKidneyRevolution.com recognizes your trust and fully respect your privacy. We will not sell your personal information (name, address, e-mail address, or credit card information) to any third party without your permission. However, there are situations when we are required by law or legal process to provide information about a customer. If you have downloaded materials or indicated that you would like to receive information from RareKidneyRevolution.com, we may send you occasional updates via e-mail. If you prefer not to receive these e-mail updates, simply follow the instructions on how to unsubscribe included in the messages you receive. If you have any questions regarding our privacy practices, please e-mail us at casey.dillon@curastrategies.com.
Changes to our Policy
Our Privacy & Security Policy is intended to provide you with the safest and most secure experience possible. Since offerings and technologies change, we reserve the right to change, modify, add or remove portions of our Policy at any time without prior notice. Please periodically review our Policy for changes. If you have any questions, or would like further clarification, please e-mail us at casey.dillon@curastrategies.com.
Disclaimer
The content provided by RareKidneyRevolution.com is for information purposes only and is in no way intended to be a substitute for medical consultation with a qualified professional. RareKidneyRevolution.com encourages Internet users to be careful when using medical information. If you are unsure about your medical condition, consult a physician. Although we carefully review our content, RareKidneyRevolution.com cannot guarantee nor take responsibility for the medical accuracy of documents we publish, nor can it assume any liability for the content of Web sites linked to our site.
The information on this Web site is provided by RareKidneyRevolution.com with the understanding that the publisher, authors, and advisors are not rendering medical or professional services. Medicine is a rapidly changing area, and efforts have been made to provide information that is medically correct at the time of initial posting. However, there may be mistakes, both typographical and in content, and subsequent findings may invalidate what is posted on this site. In portions of this site, comments are made by persons identified as physicians. No attempt has been made to verify the medical credentials of persons contributing to discussions or talks. The material provided should be used only as a general guide and not the ultimate source of information and should not be used to make personal or professional decisions.
RareKidneyRevolution.com shall have neither liability not responsibility to any person or entity with respect to any loss or damage alleged to be caused directly or indirectly by the information presented in this journal/server.
With input from patients, healthcare providers, diversity health organizations, payers and more, we've developed a set of high level recommendations to
usher in a new era of rare kidney disease care.
in partnership
with
*Retrophin rebranded as Travere Therapeutics in November 2020
*